Učitavanje...

A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice

Two recently approved PARP inhibitors provide an important new therapeutic option for patients with BRCA-mutated metastatic breast cancer. PARP inhibitors significantly prolong progression-free survival in patients, but conventional oral delivery of PARP inhibitors is hindered by limited bioavailabi...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Theranostics
Glavni autori: Zhang, Di, Baldwin, Paige, Leal, Ana S., Carapellucci, Sarah, Sridhar, Srinivas, Liby, Karen T.
Format: Artigo
Jezik:Inglês
Izdano: Ivyspring International Publisher 2019
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6735511/
https://ncbi.nlm.nih.gov/pubmed/31534547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.36281
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!